GE closes in on Applicare purchase
GE Medical Systems is reportedly in the final stages of closing its acquisition of Dutch PACS developer Applicare Medical Imaging, according to sources close to the companies. If the deal does go through, it will give GE an important boost in
GE Medical Systems is reportedly in the final stages of closing its acquisition of Dutch PACS developer Applicare Medical Imaging, according to sources close to the companies. If the deal does go through, it will give GE an important boost in penetrating the European market for PACS installations.
Milwaukee-based GE and Zeist-based Applicare have been in discussions for the past several months regarding a possible business combination. The companies held similar discussions in 1997 that never panned out.
Applicare was founded in 1987 but didnt begin to achieve widespread recognition until 1994, when its RadWorks image review software was introduced. RadWorks quickly became known as one of the more robust and cost-effective PACS viewing products, and Applicare has been successful in signing numerous agreements to supply the software to such medical imaging OEMs as Kodak and Picker. Applicare also provides RadWorks to the IBM team in the DIN-PACS project.
While GE already has its own PACS product line, the NT-based Pathspeed software, Applicare will give the company better distribution in Europe. Applicare will reportedly continue to maintain its OEM relationships once the acquisition goes through. Representatives from both companies declined to comment on the sale.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
